Prof. Dr. Ahmet Taner Sümbül

• Tumeurs du poumon 9 publications
  Source : OpenAlex / PubMed MeSHVoir les publications
• Tumeurs 8 publications
• Tumeurs du sein 8 publications
• Tumeurs de l’estomac 5 publications
• Carcinome pulmonaire non à petites cellules 5 publications
• Adénocarcinome 4 publications
• Tumeurs du foie 4 publications
• Tumeurs colorectales 3 publications
• Carcinome hépatocellulaire 3 publications
• Hypertension artérielle 2 publications
• Tumeurs des voies biliaires 2 publications
• Cholangiocarcinome 2 publications
• Mésothéliome malin 2 publications
• Mésothéliome 2 publications
• Tumeurs de la plèvre 2 publications
• Tumeurs du cerveau 2 publications
• Carcinome à cellules transitionnelles 2 publications
• Tumeurs urologiques 2 publications
• Tumeurs de la vessie 2 publications

Domaines d’intérêt médical indiqués par le médecin lui-même sur sa page du site de l’établissement. Source : medicalpark.com.tr.

Expérience

• 20032008 Dr.Arş.Gör. Çukurova Üniversitesi İç Hastalıkları ADmedicalpark.com.tr
• 20092012 Dr.Arş.Gör. Yan Dal Başkent Üniversitesi Tıbbi Onkoloji BDmedicalpark.com.tr
• 20122014 M.K.Ü. Tıp Fakültesi İç Hastalıkları Tıbbi Onkoloji Bilim Dalı Başkanı Kemoterapi birimi ve Onkoloji Kliniği sorumlu hekimimedicalpark.com.tr
• 20122013 M.K.Ü. Tıp Fakültesi Hastanesi 2. Basamak Dahiliye Yoğun Bakım sorumlu hekimimedicalpark.com.tr
• 20122013 Uzm.Dr. Mustafa Kemal Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalımedicalpark.com.tr
• 20132014 Yrd.Doç.Dr. Mustafa Kemal Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalımedicalpark.com.tr
• 20152020 Doç.Dr. Başkent Üniversitesi Tıbbi Onkoloji BDmedicalpark.com.tr
• 20202023 Prof.Dr. Başkent Üniversitesi Tıbbi Onkoloji BD Medikal Park Adana Prof. Dr.medicalpark.com.tr

Formation

• 199730.06.2003 Çukurova Üniversitesi Tıp Fakültesimedicalpark.com.tr
• 200304.11.2008 Çukurova Üniversitesi İç Hastalıkları Uzmanlıkmedicalpark.com.tr
• 200909.03.2012 Başkent Üniversitesi Tıbbi Onkoloji Yandal Uzmanlıkmedicalpark.com.tr

• SpécialitéOncologie médicalemedicalpark.com.trD’après la source
• Nom du service dans la sourceMedikal Onkoloji (Tıbbi Onkoloji)medicalpark.com.trD’après la source
• ÉtablissementMedical Park Seyhanmedicalpark.com.trD’après la source
• Sujet de travailTumeurs du poumonDéduit de 9 publications · Version du modèle —D’après la source
• Publications127 publicationsOpenAlex, ORCIDD’après la source
• ORCID0000-0002-5573-906XORCIDD’après la source
• Dernière synchronisation4 novembre 2026 20:25https://www.medicalpark.com.tr/hekimler/ahmet-taner-sumbulmedicalpark.com.tr

1. Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

   Journal of Immunotherapy, 2026

   DOI 10.1097/cji.0000000000000610 PMID 42267536 Source : OpenAlex

2. Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study

   Lung Cancer, 2026

   DOI 10.1016/j.lungcan.2026.109590 PMID 42664544 Texte intégral en libre accèsSource : ORCID

3. Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study

   JCO Oncology Practice, 2026

   DOI 10.1200/op-25-01248 PMID 42234938 Texte intégral en libre accèsSource : OpenAlex

4. Real-life efficacy and safety data of lorlatinib treatment in ROS-1–positive advanced non-small cell lung cancer: Turkish Oncology Group (TOG) study.

   Journal of Clinical Oncology, 2025

   DOI 10.1200/jco.2025.43.16_suppl.e20659 Source : OpenAlex

5. The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

   Journal of Clinical Oncology, 2025

   DOI 10.1200/jco.2025.43.16_suppl.e20501 Texte intégral en libre accèsSource : OpenAlex

6. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group

   Clinical Lung Cancer, 2025

   DOI 10.1016/j.cllc.2025.07.015 PMID 40813186 2 citations (Europe PMC) Source : OpenAlex

7. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study

   Medicina, 2025

   DOI 10.3390/medicina61040638 PMID 40282929 5 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

8. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

   Journal of Chemotherapy, 2024

   DOI 10.1080/1120009x.2024.2366683 PMID 38904164 1 citation (Europe PMC) Source : OpenAlex

9. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

   Scientific Reports, 2024

   DOI 10.1038/s41598-024-56046-w PMID 38461209 16 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

10. 46P The frequency of driver mutations in non-small cell cancer patients: Analysis of the 5064 patients in the Turkish nation-wide, observational, registurkLung study

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.102625 Texte intégral en libre accèsSource : OpenAlex